COVID-19 Antibodies in Individuals Who Have Recovered from COVID-19 Infection

Clinical Trial Title

Evaluation of COVID-19 antibody titers in plasma of individuals who have recovered from COVID-19 infection.

Contact Information

Clinical Trial Protocol Description:

Participates will donate a small blood sample. Plasma will be isolated from the blood samples. The plasma samples will be assayed for IgG, IgA and IgM antibody levels to COVID-19. In addition, the plasma samples will be assayed to determine if the antibodies are neutralizing antibodies. (This will be performed in the future when the neutralizing tests are available). The neutralizing assays need to be performed in order to determine if the antibodies are likely to protect against future infections with COVID-19. The neutralizing assays will be performed in vitro to determine if the antibodies will inhibit infection of cell cultures by the COVID-19 virus.

In addition, participates will be tested for IgG and IgM antibodies with a finger stick test (a point of care test) that will let the participants know their results at that instant.

Clinical Trial Eligibility Criteria:

To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.

Study Details

Clinical Trial Investigator

James Moy, MD

Contact Information

James Moy, MD


Rush University Medical Center

1620 W Harrison St
Chicago, IL 60612

Get Directions

Clinical Trial FAQs

Find out if a clinical trial makes sense for you.

Learn more
Learn more